Published on
Apr 28, 2025
China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
Shares of Chinese cancer drug developer Akeso slumped on Monday despite the company receiving a second marketing approval from the mainland’s drug regulator for an innovative medicine. The shares tumbled 10.2 per cent to HK$88.90 in the afternoon, after …
Source:
South China Morning Post
-
Indeterminate
